RxDoctor Payments Data

Amanda Stahl, DO

Family Medicine · Media, PANPI 1891284790

Payments from drug & device makers

$635in general payments, 2019–2025

Across 12 payments — averaging $52.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$387
  • Sanofi$122
  • Boehringer Ingelheim$50
  • Pfizer$21
  • GSK$15
  • Sanofi-aventis U.S. LLC$14
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$62298%
  • Education$132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$635 in reported general payments places this provider in the 60th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$98,460
Medicare patients
289
Services billed
1,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$78,155
MounjaroTirzepatide54$77,102
EliquisApixaban59$61,231
OzempicSemaglutide24$42,879
RybelsusSemaglutide17$32,943
TrulicityDulaglutide21$28,834
JanuviaSitagliptin Phosphate15$19,803
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$15,342
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,324
Atorvastatin Calcium394$4,633
Pantoprazole Sodium154$4,000
Rosuvastatin Calcium183$3,224
Tizanidine Hcl34$2,453
Gabapentin178$2,364
Ipratropium Bromide81$1,835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$50$78,15568 claims
Novo NordiskOzempic, Rybelsus$387$75,82241 claims
PfizerEliquis$21$61,23159 claims
MerckJanuvia$13$19,80315 claims
GSKTrelegy Ellipta$15$15,34218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Media

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →